Literature DB >> 11741480

A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues.

T Honma1, T Yoshizumi, N Hashimoto, K Hayashi, N Kawanishi, K Fukasawa, T Takaki, C Ikeura, M Ikuta, I Suzuki-Takahashi, T Hayama, S Nishimura, H Morishima.   

Abstract

Identification of a selective inhibitor for a particular protein kinase without inhibition of other kinases is critical for use as a biological tool or drug. However, this is very difficult because there are hundreds of homologous kinases and their kinase domains including the ATP binding pocket have a common folding pattern. To address this issue, we applied the following structure-based approach for designing selective Cdk4 inhibitors: (1) identification of specifically altered amino acid residues around the ATP binding pocket in Cdk4 by comparison of 390 representative kinases, (2) prediction of appropriate positions to introduce substituents in lead compounds based on the locations of the altered amino acid residues and the binding modes of lead compounds, and (3) library design to interact with the altered amino acid residues supported by de novo design programs. Accordingly, Asp99, Thr102, and Gln98 of Cdk4, which are located in the p16 binding region, were selected as first target residues for specific interactions with Cdk4. Subsequently, the 5-position of the pyrazole ring in the pyrazol-3-ylurea class of lead compound (2a) was predicted to be a suitable position to introduce substituents. We then designed a chemical library of pyrazol-3-ylurea substituted with alkylaminomethyl groups based on the output structures of de novo design programs. Thus we identified a highly selective and potent Cdk4 inhibitor, 15b, substituted with a 5-chloroindan-2-ylaminomethyl group. Compound 15b showed higher selectivity on Cdk4 over those on not only Cdk1/2 (780-fold/190-fold) but also many other kinases (>430-fold) that have been tested thus far. The structural basis for Cdk4 selective inhibition by 15b was analyzed by combining molecular modeling and the X-ray analysis of the Cdk4 mimic Cdk2-inhibitor complex. The results suggest that the hydrogen bond with the carboxyl group of Asp99 and hydrophobic van der Waals contact with the side chains of Thr102 and Gln98 are important. Compound 15b was found to cause cell cycle arrest of the Rb(+) cancer cell line in the G(1) phase, indicating that it is a good biological tool.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11741480     DOI: 10.1021/jm010326y

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  13 in total

1.  Designing the molecular future.

Authors:  Gisbert Schneider
Journal:  J Comput Aided Mol Des       Date:  2011-11-30       Impact factor: 3.686

2.  3D-QSAR and 3D-QSSR studies of thieno[2,3-d]pyrimidin-4-yl hydrazone analogues as CDK4 inhibitors by CoMFA analysis.

Authors:  Bao-qin Cai; Hai-xiao Jin; Xiao-jun Yan; Peng Zhu; Gui-xiang Hu
Journal:  Acta Pharmacol Sin       Date:  2013-10-14       Impact factor: 6.150

3.  Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors.

Authors:  Young Shin Cho; Hayley Angove; Christopher Brain; Christine Hiu-Tung Chen; Hong Cheng; Robert Cheng; Rajiv Chopra; Kristy Chung; Miles Congreve; Claudio Dagostin; Deborah J Davis; Ruth Feltell; John Giraldes; Steven D Hiscock; Sunkyu Kim; Steven Kovats; Bharat Lagu; Kim Lewry; Alice Loo; Yipin Lu; Michael Luzzio; Wiesia Maniara; Rachel McMenamin; Paul N Mortenson; Rajdeep Benning; Marc O'Reilly; David C Rees; Junqing Shen; Troy Smith; Yaping Wang; Glyn Williams; Alison J-A Woolford; Wojciech Wrona; Mei Xu; Fan Yang; Steven Howard
Journal:  ACS Med Chem Lett       Date:  2012-05-17       Impact factor: 4.345

4.  Study of a ligand complexed with Cdk2/Cdk4 by computer simulation.

Authors:  Yongjun Jiang; Jianwei Zou; Chunshan Gui
Journal:  J Mol Model       Date:  2005-06-01       Impact factor: 1.810

5.  Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence.

Authors:  Xianghong Zou; Dipankar Ray; Aileen Aziyu; Konstantin Christov; Alexander D Boiko; Andrei V Gudkov; Hiroaki Kiyokawa
Journal:  Genes Dev       Date:  2002-11-15       Impact factor: 11.361

6.  Synthetic studies toward aryl-(4-aryl-4H-[1,2,4]triazole-3-yl)-amine from 1,3-diarylthiourea as urea mimetics.

Authors:  Amarnath Natarajan; Yuhong Guo; Haribabu Arthanari; Gerhard Wagner; Jose A Halperin; Michael Chorev
Journal:  J Org Chem       Date:  2005-08-05       Impact factor: 4.354

7.  Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors.

Authors:  Karen A Rossi; Jay A Markwalder; Steven P Seitz; Chong-Hwan Chang; Sarah Cox; Michael D Boisclair; Leonardo Brizuela; Stephen L Brenner; Pieter F W Stouten
Journal:  J Comput Aided Mol Des       Date:  2005-02       Impact factor: 3.686

Review 8.  Structure-based discovery of cyclin-dependent protein kinase inhibitors.

Authors:  Mathew P Martin; Jane A Endicott; Martin E M Noble
Journal:  Essays Biochem       Date:  2017-11-08       Impact factor: 8.000

9.  Vinylogous reactivity of enol diazoacetates with donor-acceptor substituted hydrazones. Synthesis of substituted pyrazole derivatives.

Authors:  Xinfang Xu; Peter Y Zavalij; Wenhao Hu; Michael P Doyle
Journal:  J Org Chem       Date:  2013-01-24       Impact factor: 4.354

10.  Explaining the inhibition of cyclin-dependent kinase 5 by peptides derived from p25 with molecular dynamics simulations and MM-PBSA.

Authors:  Vincent B C Tan; Bing Zhang; Kian Meng Lim; Tong Earn Tay
Journal:  J Mol Model       Date:  2009-05-23       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.